Abbvie Inc Stock Price, News & Analysis

AbbVie (NYSE: ABBV) will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will take part in a fireside chat at 7:30 a.m. Central time. A live audio webcast will be available via AbbVie's investor relations site, and an archived recording will be posted later the same day.

AbbVie (NYSE: ABBV) announced U.S. FDA approval of EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma after ≥1 prior systemic therapy.

The approval follows Phase 3 EPCORE FL-1 where EPKINLY + R2 reduced risk of progression or death by 79% (HR 0.21), achieved 89% ORR and 74% complete response, and median PFS was not reached versus 11.2 months for R2. Safety was consistent with known profiles; CRS occurred in 24% (mostly Grade 1–2).

AbbVie (NYSE: ABBV) launched Second Winds, a short film about three people living with chronic lymphocytic leukemia (CLL). The film premiered on Nov 13, 2025 in Los Angeles hosted by Jesse Tyler Ferguson and is announced on Nov 14, 2025. It follows Christina, Jeff, and Alejandro and highlights resilience, community support, and quality of life.

Key cited figures: about 226,432 people with CLL in the U.S. (2022) and an estimated 23,000 new cases expected in 2025. The film is available on LA Times Studios Short Docs and AbbVie YouTube and will stream on Documentary+ in December 2025.

AbbVie (NYSE: ABBV) announced the 20 recipients of the 2025 AbbVie Migraine Career Catalyst Award™, providing each winner with $2,500 to support career development for people living with migraine. The program highlights workplace impact from migraine—noting presenteeism accounts for nearly 90% of migraine-related productivity loss—and showcases winners from diverse professions who shared stories of resilience and career disruption. The company reiterated its portfolio of three migraine treatment options and ongoing research efforts.

Allergan Aesthetics (NYSE: ABBV) will present clinical and real‑world data at the 2025 American Society for Dermatologic Surgery Annual Meeting, Nov 13–16, 2025, in Chicago. The company submitted 17 abstracts, including three oral presentations in the Cosmetic "Top Ten" session on Nov 13 highlighting Phase 3 results for first‑in‑class trenibotulinumtoxinE and a Phase 4 study of 64 units of BOTOX Cosmetic for upper facial lines.

Sessions include expert panels on hyaluronic acid fillers and a symposium on the newest BOTOX Cosmetic indication for platysma bands, plus video posters covering safety, efficacy, and patient‑reported outcomes across the portfolio.

AbbVie (NYSE:ABBV) reported third-quarter 2025 results: GAAP diluted EPS $0.10 (down 88.6%) and adjusted diluted EPS $1.86 (down 38.0%); results include an unfavorable acquired IPR&D and milestones impact of $1.50 per share. Third-quarter net revenues were $15.776 billion. Key product performance included Skyrizi $4.708B (+46.8%), Rinvoq $2.184B (+35.3%), Humira $993M (-55.4%), Botox therapeutic $985M (+16.1%), and Qulipta $288M (+64.1%). AbbVie raised full-year 2025 adjusted EPS guidance to $10.61–$10.65 (includes $2.05/share IPR&D impact YTD) and declared a 5.5% dividend increase payable Feb 17, 2026.

Allergan Aesthetics (NYSE: ABBV) announced that the seventh annual BOTOX® Cosmetic Day will be held on Wednesday, November 19, 2025, offering exclusive promotions through the Allē app.

Key offers include a BOGO $50 gift card (purchase one $50 card, receive a $50 card free) starting 9 a.m. PT on 11/19 while supplies last, and a chance to win $25,000 for Allē members who register by 11/30, book a consultation, and complete treatment by 12/12. Allē has 8 million members and supports purchases across 30,000 U.S. practices. The release reiterates BOTOX Cosmetic's FDA‑approved uses for facial lines and references clinical satisfaction data and payment-plan options through Cherry.

AbbVie (NYSE: ABBV) reported positive topline results from two replicate Phase 3 studies of upadacitinib 15 mg once daily in adults and adolescents with non-segmental vitiligo, announcing that both studies met co-primary endpoints at week 48 for T-VASI 50 (≥50% total-body repigmentation) and F-VASI 75 (≥75% facial repigmentation).

Key efficacy: T-VASI 50 rates were 19.4% and 21.5% on drug versus 5.9% placebo; F-VASI 75 rates were 25.2% and 23.4% on drug versus 5.9% and 6.9% placebo; F-VASI 50 was 48.1% and 43.4% versus 12.7% and 12.9% placebo. Safety was consistent with known profiles: common TEAEs included upper respiratory infection, acne and nasopharyngitis; no new safety signals, no adjudicated MACE or VTE.

Use in non-segmental vitiligo is not approved and has not been evaluated by regulators.

Allergan Aesthetics (NYSE:ABBV) renewed its seven-year partnership with Girls Inc. on Oct 28, 2025

Key initiatives include an Allergan Medical Institute (AMI) Atlanta Training Center visit with a panel of local women healthcare providers and the SkinSpirit Gives campaign inviting client donations from Nov 1–Nov 15, 2025. Donations will fund STEM programming, mentorship, and career exploration for more than 120,000 girls across 75 affiliates in the U.S. and Canada. The announcement emphasizes mentorship and resources to increase female representation in STEM, noting women hold 18% of U.S. STEM jobs and 55% of girls express STEM interest.